

<i>Title</i>	Prospective, phase II trial using Capecitabine and Trastuzumab for therapy of female patients with cerebral metastasizing, HER2 overexpressing breast cancer
<i>Sponsor code</i>	TRAS-LIQ-2004
<i>EudraCT number</i>	2007-003634-42
<i>Results</i>	Prematurely study end in January 27 th 2011 (only 1 patient recruited)